Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression

Ng, Cheng-Ann Winston; Jiang, Aiting; Toh, Emma Min Shuen; Ng, Cheng Han; Ong, Zhi Hao; Peng, Siyu; Tham, Hui Yu; Sundar, Raghav; Chong, Choon Seng; Khoo, Chin Meng

doi:10.1007/s00384-020-03676-x

Cited by 82 publications

(73 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results require further studies, but the results are promising [34]. It has been reported that the use of metformin is associated with a reduction in the risk of cancer: colorectal cancer [35][36][37][38][39][40], breast cancer [41,42], lung cancer [43], liver cancer [44], stomach cancer [45,46], and skin cancer [47]. A 2019 meta-analysis compared the cancer risk in patients with type 2 diabetes using metformin monotherapy compared to patients using sulphonylurea monotherapy.…”

Section: Metformin and Cancermentioning

confidence: 99%

“…These changes may contribute to the inhibition of the development of colorectal cancer. The results of many studies indicate that metformin may play an important role in reducing the incidence of colorectal cancer [36][37][38][39][40]. The analysis of the Markov model showed that patients with type 2 diabetes treated with metformin had a lower incidence of colorectal cancer compared to patients not using metformin (1.670% vs. 2.146%, respectively; p = 0.016) [38].…”

Section: Colon Cancermentioning

confidence: 99%

See 1 more Smart Citation

Metformin – a new approach

Cwynar-Zając¹

2021

pedm

View full text Add to dashboard Cite

Metformin is a widely used biguanide drug recommended as a first-line antidiabetic for type 2 diabetes. Currently, metformin is used not only in the treatment of diabetes but also in other diseases. Some studies have shown that metformin causes weight loss in insulin-sensitive and insulin-resistant overweight and obese patients. Metformin is an effective and safe option for women with gestational diabetes and type 2 diabetes in pregnancy, and it may also increase the ovulation rate in patients with polycystic ovary syndrome (PCOS). Longer survival times have been observed in cancer patients using metformin. Metformin has been shown to significantly correlate with lower mortality in obese or type 2 diabetic women hospitalized for COVID-19. It also has a protective effect on the development and progression of many types of cancer. The mechanisms of action of metformin are complex and still not fully understood. Metformin has been shown to act through both AMP-activated protein kinase (AMPK)-dependent mechanisms and AMPK-independent mechanisms. This paper presents the benefits of using metformin in the treatment of various diseases.

show abstract

Section: Metformin and Cancermentioning

confidence: 99%

Section: Colon Cancermentioning

confidence: 99%

Metformin – a new approach

Cwynar-Zając¹

2021

pedm

View full text Add to dashboard Cite

show abstract

“…1 This means that NSAID users were more likely to have been taking other drugs such as metformin, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. 2,3 In addition, NSAID users often take other drugs for pain control, such as systemic slow-acting drugs. 4 These drugs reduce CRC risk and, like aspirin and statins, their use arguably should have been adjusted for in the model.…”

Section: Editorsmentioning

confidence: 99%

“…First, NSAID users were older and had a higher proportion of hypertension, diabetes and hyperlipidaemia than non‐users (Table 1 of the publication) 1 . This means that NSAID users were more likely to have been taking other drugs such as metformin, angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers 2,3 . In addition, NSAID users often take other drugs for pain control, such as systemic slow‐acting drugs 4 .…”

mentioning

confidence: 99%

Letter: nonsteroidal anti‐inflammatory drugs reduce the risk of post‐colonoscopy colorectal cancer

Tantai

Liu

Wang

2020

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“… 11 − 13 This observation was also confirmed by the results of many meta-analyses. 14 − 16 Metformin is also garnering attention for its potential in treating polycystic ovary syndrome. 9 , 17 …”

Section: Introductionmentioning

confidence: 99%

Why Should Metformin Not Be Given in Advanced Kidney Disease? Potential Leads from Computer Simulations

Maleš

Požar

2021

ACS Omega

View full text Add to dashboard Cite

Metformin is considered as the go-to drug in the treatment of diabetes. However, it is either prescribed in lower doses or not prescribed at all to patients with kidney problems. To find a potential explanation for this practice, we employed atomistic-level computer simulations to simulate the transport of metformin through multidrug and toxin extrusion 1 (MATE1), a protein known to play a key role in the expulsion of metformin into urine. Herein, we examine the hydrogen bonding between MATE1 and one or more metformin molecules. The simulation results indicate that metformin continuously forms and breaks off hydrogen bonds with MATE1 residues. However, the mean hydrogen bond lifetimes increase for an order of magnitude when three metformin molecules are inserted instead of one. This new insight into the metformin transport process may provide the molecular foundation behind the clinical practice of not prescribing metformin to kidney disease patients.

show abstract

Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression

Cited by 82 publications

References 96 publications

Metformin – a new approach

Metformin – a new approach

Letter: nonsteroidal anti‐inflammatory drugs reduce the risk of post‐colonoscopy colorectal cancer

Why Should Metformin Not Be Given in Advanced Kidney Disease? Potential Leads from Computer Simulations

Contact Info

Product

Resources

About